After considering the feedback from consultation, the appraisal committee has prepared a final appraisal document (FAD) on pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) and submitted it to NICE.
The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for NICE's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5:00pm, Thursday 18 February 2021.
This page was last updated: